HTG Molecular Diagnostics Inc (NASDAQ:HTGM) dropped 2.9% during trading on Thursday . The company traded as low as $2.30 and last traded at $2.71, with a volume of 54,989 shares trading hands. The stock had previously closed at $2.79.

HTGM has been the subject of a number of analyst reports. Leerink Swann reissued an “outperform” rating and issued a $5.00 price target (down from $10.00) on shares of HTG Molecular Diagnostics in a research report on Monday, March 28th. Canaccord Genuity lowered their price target on HTG Molecular Diagnostics from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, April 4th. Finally, Zacks Investment Research lowered HTG Molecular Diagnostics from a “hold” rating to a “sell” rating in a research report on Monday, April 4th.

The company’s market capitalization is $19.13 million. The company’s 50 day moving average price is $2.81 and its 200-day moving average price is $3.04.

HTG Molecular Diagnostics (NASDAQ:HTGM) last issued its quarterly earnings data on Thursday, May 12th. The company reported ($1.02) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.83) by $0.19. On average, equities research analysts anticipate that HTG Molecular Diagnostics Inc will post ($3.91) earnings per share for the current fiscal year.

HTG Molecular Diagnostics, Inc is a provider of instruments and reagents for molecular profiling applications. The Company has developed and markets a technology platform for the routine use of complex molecular profiling. The Company’s HTG Edge platform, consisting of instrumentation, including HTG Edge and HTG EdgeSeq systems, consumables and software analytics, is used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.